Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Effect of recombinant human erythropoietin on insulin resistance in hemodialysis patients.

Khedr E, El-Sharkawy M, Abdulwahab S, Eldin EN, Ali M, Youssif A, Ahmed B.

Hemodial Int. 2009 Jul;13(3):340-6. doi: 10.1111/j.1542-4758.2009.00367.x. Epub 2009 Jul 3.

PMID:
19552740
2.

The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin.

Tuzcu A, Bahceci M, Yilmaz E, Bahceci S, Tuzcu S.

Horm Metab Res. 2004 Oct;36(10):716-20.

PMID:
15523598
4.
5.
6.

Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.

Movilli E, Cancarini GC, Zani R, Camerini C, Sandrini M, Maiorca R.

Nephrol Dial Transplant. 2001 Jan;16(1):111-4.

PMID:
11209002
7.
8.

Insulin resistance in dialysis versus non dialysis end stage renal disease patients without diabetes.

Satirapoj B, Supasyndh O, Phantana-Angkul P, Ruangkanchanasetr P, Nata N, Chaiprasert A, Kanjanakul I, Choovichian P.

J Med Assoc Thai. 2011 Sep;94 Suppl 4:S87-93.

PMID:
22043573
9.

Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.

Allegra V, Martimbianco L, Vasile A.

Nephrol Dial Transplant. 1997 May;12(5):924-32.

PMID:
9175044
10.

Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.

Gallucci MT, Lubrano R, Meloni C, Morosetti M, Manca di Villahermosa S, Scoppi P, Palombo G, Castello MA, Casciani CU.

Clin Nephrol. 1999 Oct;52(4):239-45.

PMID:
10543326
11.
12.

High blood soluble receptor p80 for tumour necrosis factor-alpha is associated with erythropoietin resistance in haemodialysis patients.

Kato A, Odamaki M, Takita T, Furuhashi M, Maruyama Y, Hishida A.

Nephrol Dial Transplant. 2001 Sep;16(9):1838-44.

PMID:
11522867
13.

Anemia and carnitine supplementation in hemodialyzed patients.

Kletzmayr J, Mayer G, Legenstein E, Heinz-Peer G, Leitha T, Hörl WH, Kovarik J.

Kidney Int Suppl. 1999 Mar;69:S93-106.

PMID:
10084293
14.

Blood 8-hydroxy-2'-deoxyguanosine is associated with erythropoietin resistance in haemodialysis patients.

Kato A, Odamaki M, Hishida A.

Nephrol Dial Transplant. 2003 May;18(5):931-6.

PMID:
12686667
15.

Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD.

Lin SH, Lin YF, Kuo SW, Hsu YJ, Hung YJ.

Am J Kidney Dis. 2003 Oct;42(4):774-80.

PMID:
14520628
16.

Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.

Nakamoto H, Mimura T, Honda N.

Hemodial Int. 2008 Oct;12 Suppl 2:S9-S14. doi: 10.1111/j.1542-4758.2008.00317.x.

PMID:
18837771
17.
18.
19.

[Effect of erythropoietin therapy on serum lipoprotein levels in patients on hemodialysis].

Kes P, Bobić I, Reiner Z, Ratković-Gusić I.

Lijec Vjesn. 2002 May;124(5):146-50. Croatian.

PMID:
12152415
20.

Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin.

Takeda A, Toda T, Shinohara S, Mogi Y, Matsui N.

Am J Kidney Dis. 2002 Jul;40(1):104-9.

PMID:
12087567

Supplemental Content

Support Center